Trishula Revenue and Competitors

Location

Total Funding

Industry

Estimated Revenue & Valuation

Name	Title	Email/Phone
1 Alan Luk	VP, Head CMC	Reveal Email/Phone
2 Siddhartha Mitra	Chief Medical Officer	Reveal Email/Phone
3 Anh Tran	Executive Director Clinical Operations	Reveal Email/Phone
4 Rishi Sharma	Sr. Clinical Trial Manager	Reveal Email/Phone
5 Thomas Jahn	Global Clinical Program Lead, Hematology ⋅ AstraZeneca	Reveal Email/Phone

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 DiaCarta	$5.4M	70	-8%	$53M	N/A
#2 Mission Bio	$32.4M	167	-26%	$110M	N/A
#3 Quadrants Scien...	$0.9M	6	0%	N/A	N/A
#4 Calcilytix Ther...	$2.8M	18	13%	N/A	N/A
#5 Ravata Solution...	$0.8M	5	-50%	N/A	N/A
#6 Range Biotechno...	$0.8M	10	0%	N/A	N/A
#7 Mission Barns	$14M	90	-12%	N/A	N/A
#8 Geron Corporati...	$0.4M	336	10%	$236.7M	N/A
#9 Mindstrong	$4.8M	62	-74%	$160M	N/A
#10 SafeTraces	$3.7M	24	-8%	N/A	N/A

keywords:N/A

N/A

Total Funding

Number of Employees

$2.8M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First...

Trishula Therapeutics has reported encouraging initial data from an ongoing Phase I trial of its anti-CD39 antibody TTX-030 with budigalimab...

Trishula is a privately held company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody, in collaboration with AbbVie...

Company Name	Revenue	Number of Employees	Employee Growth	Total Funding
#1 IgGenix	$1.4M	18	-25%	$35M
#2 Vital Restorati...	$3.1M	18	-10%	N/A
#3 Netswitch Techn...	$1.5M	18	-5%	N/A
#4 Royal Cafe	$3.8M	20	0%	N/A
#5 CERO Therapeuti...	$3.1M	20	25%	$0.125M